BioCentury | Oct 13, 2017
Product Development

Eyeing complement data

...They were Alexion Pharmaceuticals Inc. ’s marketed drug Soliris eculizumab and Novartis AG’s investigational compound LFG316... Soliris missed the primary endpoint of decreasing GA growth vs. placebo at 26 weeks; LFG316...
...He thinks other factors besides the target could have explained the failures of Soliris and LFG316...
BioCentury | Aug 29, 2017
Distillery Therapeutics

Infectious disease

...humanized mAb against C5, in Phase III testing for the two indications. Novartis AG has LFG316...
BioCentury | Jun 2, 2014
Emerging Company Profile

Panoptes: Dual attack in uveitis

...from Xoma Corp. and Servier . It is in Phase III testing. Novartis AG 's LFG316...
Items per page:
1 - 3 of 3